Aficamten’s patent risk just moved from filing footnote to federal court

The legal risk was not entirely new. Cytokinetics had previously disclosed awareness that U.S. Patent No. 12,616,697 had been issued to MyoKardia, making the possibility of litigation part of the existing aficamten risk framework.

What changed is the escalation from patent awareness to an affirmative federal lawsuit. The company filed in Delaware seeking declarations that MYQORZO does not infringe the patent and that the patent claims are invalid, plus injunctions against infringement threats and potential recovery of costs and attorneys’ fees (Item 8.01 — Other Events).

This is strategically defensive, not a resolution. The complaint may be intended to clear uncertainty around MYQORZO and protect customers and distributors, but the filing provides no court ruling, settlement, license, damages outcome, or change to the drug’s commercial status. The requested relief is the company’s position, not an established result (Item 8.01 — Other Events).

Net: a mixed development versus expectations. The lawsuit removes ambiguity about Cytokinetics’ chosen response and signals that patent exposure is becoming an active legal dispute, but the underlying risk was already disclosed and the outcome remains uncertain. There is therefore no clean earnings-style beat or miss; the filing modestly increases near-term legal focus without resolving the commercial question.